Abstract
The investigation and manipulation of cellular processes with subcellular resolution requires non‐invasive tools with spatiotemporal precision and reversibility. Building on the interaction of the photoreceptor PAL with an RNA aptamer, we describe a variation of the CRISPR/dCAS9 system for light‐controlled activation of gene expression. This platform significantly reduces the coding space required for genetic manipulation and provides a strong on‐switch with almost no residual activity in the dark. It adds to the current set of modular building blocks for synthetic biological circuit design and is broadly applicable.
Keywords: aptamers, gene expression, synthetic biology
A three‐component light switch for programmable gene activation is reported. A photoreceptor aptamer pair facilitates reversible control of gene expression and broadens the optoribogenetic toolbox.
Clustered regularly interspaced short palindromic repeats (CRISPR) loci and the CRISPR‐associated (cas) genes encode for an RNA‐guided adaptive immune system in prokaryotes. [1] The Cas9 protein, which is used as a programmable nuclease, specifically binds and cleaves selected DNA sequences and became a powerful tool for biotechnological research. [2] Because of the easy implementation, CRISPR has become a standard in genome editing, gene regulation or DNA imaging. [3] The CRISPR/Cas systems can be subdivided into three main types (Type I, II, and III) that differ in their corresponding Cas proteins. [4] Among these, the Type II Cas9 protein from S. pyogenes is the best studied. [5] The nuclease deficient mutant of Cas9, dubbed dCas9, enables CRISPR/dCas9 to be used as a biological navigation system, which can be functionally extended by generating effector‐dCas9 fusion proteins. Thereby, new functions such as transcriptional activation, DNA tagging, chromatin purification, RNA recruitment, DNA looping, and chromatin modification are accessible. Transcriptional activation, named CRISPR activation (CRISPRa), is achieved by fusing transactivation domains, e.g., VP64, p65, HSF1, and rta to dCas9[ 3e , 6 ] and optogenetic control is attained using CIB1 and CRY2 as photodimerizable components fused to transactivation and effector proteins. [7] Optogenetic dCas9‐based activation systems involve a cluster of proteins, that overstrain the capacity of single viral payload in regard of coding space. CRY2/CIB1‐based methods, in turn, are limited by CRY2 homodimerization in light [8] and split dCas9 variants are associated with higher background activity and slow off‐rates. [7a] In our approach, we constructed sgRNAs having short RNA aptamer domains binding to the protein PAL. [9] PAL is a LOV domain photoreceptor and interacts reversibly with the aptamer 53. [9] In previous work, we embedded this aptamer into the 5′‐untranslated region of mRNA molecules, by which a light‐dependent off‐switch of gene expression was generated. [9] We now sought to create on‐switches based on the PAL:aptamer system that enable the activation of gene expression upon irradiation rather than inhibiting. To this end, we created an RNA‐protein interface that reversibly activates gene expression in response to blue light by fusing PAL to the activator domains p65 and HSF1 (p65‐HSF1‐PAL, dubbed PHP). Irradiation thus induces recruitment of PHP to sgRNA tagged loci triggering transcription and gene expression (Figure 1 a).
We introduced aptamer 53 into the tetraloop (TL) and stem‐loop 2 (SL2) of sgRNAs with different stem lengths (SG6, SG9, and SG12) to allow variable positioning of PHP for transcription activation (Figure 2 a, Figure S1a–c, Supporting Information) [6c] and to avoid negative impact on PAL binding in light by putative steric hindrance of the sgRNA/dCas9 complex. We first tested the capability of the modified sgRNAs to mediate Cas9‐dependent cleavage of target DNA in vitro and found explicit cleavage activity for sgRNAs SG6 and SG9 in comparison with the native, that is, non‐modified sgRNA (control) and sgRNA 2.0, [6c] when a targeting seed sequence was used (Figure S1d, Supporting Information). Cleavage efficiency mediated by SG12 was diminished (Figure S2a, Supporting Information) when a targeting seed sequence was used. sgRNAs programmed with a non‐binding [10] seed sequence showed no or strongly reduced activity. We next investigated transactivation of gene expression in mammalian cells. Nuclear expression of PHP in HeLa cells and the switching activity of its PAL domain was confirmed by fluorescence microscopy (Figure S2b,c and Note S2, Supporting Information). In initial experiments, an eBFP reporter was used containing eight sgRNA binding sites upstream of a minimal CMV promoter (Figure 2 a). We transiently co‐expressed dCas9, the eBFP reporter, PHP and sgRNA SG6 in HeLa cells. As control, we included the SAM system using MS2‐p65‐HSF1 (MPH) and its corresponding sgRNA 2.0 but using dCas9 without VP64. [6c] Light‐dependent and aptamer specific activation of gene expression was found for sgRNA SG6 when co‐expressed with PHP, whereas no eBFP was detected in darkness (Figure S2d,e, Supporting Information). Activation of gene expression was also observed using MPH and sgRNA 2.0, which is independent of the irradiation status (Figure S2d, Supporting Information). Expression of MPH and SG6 or PHP and sgRNA 2.0 induced gene expression neither in darkness nor in light (Figure S2d, Supporting Information). We optimized the ratio of the plasmids used for transfection (Figure S2f, Supporting Information) and applied these to sgRNAs SG9 and SG12. Compared to SG6, a stronger induction of gene expression was found when using sgRNAs with stem lengths of 9 or 12 nts (Figure 2 b, Figure S1 and S2g,h, Supporting Information). No activation of gene expression was observed in darkness or when PAL‐binding incompetent point mutants of the aptamers were used, having a point mutation in the aptamer domain embedded in TL and in SL2 (SG6M21, SG9M21, or SG12M21) (Figure 2 b, Figure S1 and S2g,h, Supporting Information). We analyzed the tunability of the system, that is, dependency of gene expression on light intensity using SG9. Increasing light intensity results in an enhanced eBFP expression and a maximum at a value of 100 μW cm−2 (Figure 2 c). The activation efficacy was also found to be slightly stronger when using PHP compared to a variant with an altered order of the effector domains (HSF1‐p65‐PAL, HPP) (Figure 2 d). Of note, mutation of only one of the two aptamer domains (SG9M21TL, only mutated in the aptamer domain of the tetraloop; SG9M21SL2, only mutated in the aptamer domain of stem‐loop 2) in the sgRNAs leads to a strong reduction in activity (Figure 2 e, Figure S1, Supporting Information), indicating that both aptamer domains are necessary to mediate the transactivation of gene expression. This superiority of two aptamers over one was also found when using the MS2 system. [6c] This observation might be explained by synergistic effects leading to higher local concentrations of transactivation domains upstream of the promoter. Furthermore, cooperative effects in PHP‐aptamer binding, mediated by dimer aptamer arrangements in the respective sgRNAs might support the recruitment and positioning of the transactivation domain. Similar results were observed when using Metridia luciferase as reporter gene (Figure 2 f, Figure S2i, Supporting Information), although total expression levels were lower compared to eBFP (Figure S2g, Supporting Information). Metridia luciferase is secreted into the cells’ supernatant and can therefore be utilized to investigate the reversibility of the PHP system. We first tested Metridia luciferase activity with increasing incubation times for an optimal signal‐to‐noise ratio (Figure S2j, Supporting Information). Luciferase activity was then measured 12 h after transfection and irradiation (Figure 2 g), after which the cells were kept in darkness for further 12 h. Reporter levels were found to be reduced by 50 % and could be fully restored by irradiation (Figure 2 g). Given the average half‐life of mRNAs in human cells of approx. 10 h, [11] this result demonstrates reversibility of the PAL‐driven gene expression by light.
We next applied the PHP system to control the expression of an endogenous gene, exemplified by human achaete‐scute homolog 1 (ASCL1). ASCL1 encodes a transcription factor, which is involved in neuronal differentiation. In HeLa cells the expression of ASCL1 is low, making it a suitable target gene for artificial upregulation leading to high dynamic ranges.[ 6c , 7a ] Initially, we used sgRNAs with a 9nt stem and targeting six different loci upstream of the human ASCL1 promoter (SG9#1 to SG9#6, Figure 3 a, Table S1, Supporting Information). For comparison, we adapted the ASCL1 loci from Nihongaki et al., [7a] showing transcriptional activation of ASCL1 regulation using the CPTS2.0 system. Among the adapted sgRNAs, those targeting positions #2 and #4 showed the strongest activation of ASCL1 expression in light using PHP (Figure 3 b). While loci #4 was also found to be effective in mediating transcriptional activation using the CPTS2.0 system, loci #2 was more potent when the SAM and split‐CPTS2.0 systems were used. [7a] These findings indicate, that the combination of the effector system and loci is critical for achieving potent transcriptional activation. SG9#2 and SG9#4 revealed fold changes (light vs. dark) of 99 and 21, respectively (Figure 3 c). These values were further increased using both sgRNAs simultaneously (546, Figure 3 c). In our hands, the PHP:SG9#2 combination was found to be as potent as the MPH:sgRNA2.0 combination in gene activation, whereas the latter being light independent (Figure 3 c). The highest induction of transcription is often achieved, when sgRNAs are positioned between −25 and −550 bp upstream of the promoter, [12] from which the highest activity is most likely between −25 and −200 bp. [6c] The sgRNAs SG9#2 and SG9#4 are located to this region. The less effective loci might be affected by an unfavorable orientation on the DNA towards the promoter or by nucleosomes that impact the dCas9‐complex from binding to the DNA. [13]
In conclusion, we report on an optoribogenetic method that enables the reversible activation of gene expression with blue light. The described method makes use of a light‐dependent RNA‐protein interaction and reduces the number of components of CRISPR/dCas9 [7a] approaches to three, that is, sgRNAs, dCas9 and PHP. The coding space of the CPTS2.0 system [7a] is 4254 bases, whereas PHP requires only 50 % of that coding space (i.e. 2109 bases). This compact system needs less coding space, which might allow the integration of all components in a single virus. As this option is not yet available from other systems, stable CRISPR cell lines can be generated to be transduced with corresponding sgRNAs.[ 6c , 11 ] For example, cells or organisms that stably express dCas9 might be used, further underscoring the compactness of the light‐dependent PHP effector system. Moreover, the PHP system is not affected by homodimerization and background activity. We show, that different stem lengths influence the activity of sgRNAs, whereas results found in vitro not strictly reflect the situation observed from experiments in cells. This finding might be due to differences in intracellular environment that impact RNA performance, e.g., molecular crowding and ion composition. [15] We anticipate our approach being broadly applicable in cells and in vivo, as well as for synthetic biology approaches, e.g., as building block in a multi‐component activation system that combines several aptamers [16] and thereby extends the complexity of available synthetic gene circuits.
Conflict of interest
The authors declare no conflict of interest.
Supporting information
Acknowledgements
This work was supported by funds from the European Union ERC (“OptoRibo”, 615381) to G.M. and the German Research Council (grants MA3442/5‐1 and 5‐2 and SFB1089‐P1 to G.M.). Open access funding enabled and organized by Projekt DEAL.
C. Renzl, A. Kakoti, G. Mayer, Angew. Chem. Int. Ed. 2020, 59, 22414.
References
- 1. Barrangou R., Fremaux C., Deveau H., Richards M., Boyaval P., Moineau S., Romero D. A., Horvath P., Science 2007, 315, 1709–1712. [DOI] [PubMed] [Google Scholar]
- 2.
- 2a. Leenay R. T., Beisel C. L., J. Mol. Biol. 2017, 429, 177–191; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2b. Hsu P. D., Lander E. S., Zhang F., Cell 2014, 157, 1262–1278; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2c. Doudna J. A., Charpentier E., Science 2014, 346, 1258096. [DOI] [PubMed] [Google Scholar]
- 3.
- 3a. Anton T., Bultmann S., Leonhardt H., Markaki Y., Nucleus 2014, 5, 163–172; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3b. Cong L., Ran F. A., Cox D., Lin S., Barretto R., Habib N., Hsu P. D., Wu X., Jiang W., Marraffini L. A., Zhang F., Science 2013, 339, 819–823; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3c. Luo M. L., Mullis A. S., Leenay R. T., Beisel C. L., Nucleic Acids Res. 2015, 43, 674–681; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3d. Chen B., Gilbert L. A., Cimini B. A., Schnitzbauer J., Zhang W., Li G. W., Park J., Blackburn E. H., Weissman J. S., Qi L. S., Huang B., Cell 2013, 155, 1479–1491; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3e. Gilbert L. A., Larson M. H., Morsut L., Liu Z., Brar G. A., Torres S. E., Stern-Ginossar N., Brandman O., Whitehead E. H., Doudna J. A., Lim W. A., Weissman J. S., Qi L. S., Cell 2013, 154, 442–451; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3f. Iwasaki R. S., Ozdilek B. A., Garst A. D., Choudhury A., Batey R. T., Nat. Commun. 2020, 11, 1394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Makarova K. S., Haft D. H., Barrangou R., Brouns S. J., Charpentier E., Horvath P., Moineau S., Mojica F. J., Wolf Y. I., Yakunin A. F., van der Oost J., Koonin E. V., Nat. Rev. Microbiol. 2011, 9, 467–477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Ratner H. K., Sampson T. R., Weiss D. S., Cold Spring Harb. Protoc. 2016, 2016, pdb.top088849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.
- 6a. Bassett A. R., Liu J. L., J. Genet. Genomics 2014, 41, 7–19; [DOI] [PubMed] [Google Scholar]
- 6b. Chavez A., Scheiman J., Vora S., Pruitt B. W., Tuttle M., lyer E. P. R., Lin S., Kiani S., Guzman C. D., Wiegand D. J., Ter-Ovanesyan D., Braff J. L., Davidsohn N., Housden B. E., Perrimon N., Weiss R., Aach J., Collins J. J., Church G. M., Nat. Methods 2015, 12, 326–328; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6c. Konermann S., Brigham M. D., Trevino A. E., Joung J., Abudayyeh O. O., Barcena C., Hsu P. D., Habib N., Gootenberg J. S., Nishimasu H., Nureki O., Zhang F., Nature 2015, 517, 583–588; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6d. Jia Y., Xu R. G., Ren X., Ewen-Campen B., Rajakumar R., Zirin J., Yang-Zhou D., Zhu R., Wang F., Mao D., Peng P., Qiao H. H., Wang X., Liu L. P., Xu B., Ji J. Y., Liu Q., Sun J., Perrimon N., Ni J. Q., Proc. Natl. Acad. Sci. USA 2018, 115, 4719–4724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.
- 7a. Nihongaki Y., Furuhata Y., Otabe T., Hasegawa S., Yoshimoto K., Sato M., Nat. Methods 2017, 14, 963–966; [DOI] [PubMed] [Google Scholar]
- 7b. Polstein L. R., Gersbach C. A., Nat. Chem. Biol. 2015, 11, 198–200; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7c. Nihongaki Y., Yamamoto S., Kawano F., Suzuki H., Sato M., Chem. Biol. 2015, 22, 169–174. [DOI] [PubMed] [Google Scholar]
- 8. Hallett R. A., Zimmerman S. P., Yumerefendi H., Bear J. E., Kuhlman B., ACS Synth. Biol. 2016, 5, 53–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Weber A. M., Kaiser J., Ziegler T., Pilsl S., Renzl C., Sixt L., Pietruschka G., Moniot S., Kakoti A., Juraschitz M., Schrottke S., Lledo Bryant L., Steegborn C., Bittl R., Mayer G., Moglich A., Nat. Chem. Biol. 2019, 15, 1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Lawhorn I. E., Ferreira J. P., Wang C. L., PLoS One 2014, 9, e113232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Shao J., Wang M., Yu G., Zhu S., Yu Y., Heng B. C., Wu J., Ye H., Proc. Natl. Acad. Sci. USA 2018, 115, E6722–E6730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Horlbeck M. A., Gilbert L. A., Villalta J. E., Adamson B., Pak R. A., Chen Y., Fields A. P., Park C. Y., Corn J. E., Kampmann M., Weissman J. S., eLife 2016, 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Horlbeck M. A., Witkowsky L. B., Guglielmi B., Replogle J. M., Gilbert L. A., Villalta J. E., Torigoe S. E., Tjian R., Weissman J. S., eLife 2016, 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Kiani S., Chavez A., Tuttle M., Hall R. N., Chari R., Ter-Ovanesyan D., Qian J., Pruitt B. W., Beal J., Vora S., Buchthal J., Kowal E. J., Ebrahimkhani M. R., Collins J. J., Weiss R., Church G., Nat. Methods 2015, 12, 1051–1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.
- 15a. Dhar A., Girdhar K., Singh D., Gelman H., Ebbinghaus S., Gruebele M., Biophys. J. 2011, 101, 421–430; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15b. Richter K., Nessling M., Lichter P., Biochim. Biophys. Acta Mol. Cell Res. 2008, 1783, 2100–2107. [DOI] [PubMed] [Google Scholar]
- 16. Zalatan J. G., Lee M. E., Almeida R., Gilbert L. A., Whitehead E. H., La Russa M., Tsai J. C., Weissman J. S., Dueber J. E., Qi L. S., Lim W. A., Cell 2015, 160, 339–350. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.